Advertisement

Pharmacokinetics of [125I]-recombinant human interleukin-11:

2. Placental transfer and excretion into milk after subcutaneous administration to rats
  • T. Uchida
  • K. Aoyama
  • K. Mori
  • T. Usui
  • T. Watanabe
  • Y. Takariki
  • N. Asahara
  • M. Hirose
  • T. Kimura
  • M. Tateishi
  • S. Higuchi
Article

Summary

Placental transfer and excretion into milk of [125I]-rhIL-11 (recombinant human interleukin-11) after subcutaneous administration in female rats were investigated. After administration of [125I]-rhIL-11 to rats on the 14th day of gestation, radioactivity in the kidney was the highest among excised tissues, being 3 times higher than that in the plasma at 1.5 h. Radioactivity in other tissues, including the mammary gland, ovary, uterus, placenta and amniotic fluid, was lower than that in the plasma. Although radioactivity in fetuses was detected 6 h after administration, the level was only 2% of the plasma concentration in dams, and the radioactivity was not found in fetal-derived TCA precipitates. These results indicate that rhIL-11 does not readily pass through the placenta into the fetus. After subcutaneous administration of [125I]-rhIL-11 to lactating rats 14 days after delivery, radioactivity in milk was 1.1–1.6 times that in the plasma of dams. Radioactivity in clotted milk in the stomachs of suckling infants was almost equal to that in the dam’s milk; however, only a small amount of radioactivity was detected in infant kidneys.

Keywords

Recombinant human interleukin-11 subcutaneous administration placental transfer excretion into milk 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yonemura Y., Kawakita M., Masuda T., Fujimoto K., Takatsuki K. (1993): Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin-6. Br. J. Haematol., 84, 16–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Neben T.Y., Loebelenz J., Hayes L. et al. (1993): Recombinant human interleukin-11 stimulates megakaryocytopoietisis and increases peripheral platelets in normal and splenectomized mice. Blood, 81, 901–908.PubMedGoogle Scholar
  3. 3.
    Hangog G., Yin T., Cooper S., Schendel P., Yang Y.C., Broxmeyer H.E. (1993): In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood, 81, 965–972.Google Scholar
  4. 4.
    Yin T., Miyazawa K., Yang Y. (1992): Characterization of interleukin-11 receptor and protein tyrosine phosphorylation induced by interleukin-11 in mouse 3T3-L1 cells. J. Biol. Chem., 267, 8347–8351.PubMedGoogle Scholar
  5. 5.
    Misaizu T., Shinkai H., Hirosawa T., Kikuchi K., Tokiwa T. (1990): Metabolic fate of KRN8601: transfer of125I-KRN8601 into fetus and milk in pregnant or lactating rats. Xenobio. Drug Metab. Dispos., 5, 307–314.Google Scholar
  6. 6.
    Niwa T., Suzuki M., Takano N., Fujimura Y. (1994): Studies on metabolic fate of avicatonin(II) — feto-placental transfer and excretion into milk in rats. Jpn. Pharmacol. Ther., 22, S3315-S3323.Google Scholar
  7. 7.
    Oikawa K., Kamimura H., Watanabe T. et al. (1996): Metabolic fate of YM866, a novel fibrinolytic agent (II) feto-placental transfer and excretion into milk in rats. Xenobiot. Drug Metab. Dispos., 11, 30–37.Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • T. Uchida
    • 1
  • K. Aoyama
    • 1
  • K. Mori
    • 1
  • T. Usui
    • 1
  • T. Watanabe
    • 1
  • Y. Takariki
    • 2
  • N. Asahara
    • 2
  • M. Hirose
    • 2
  • T. Kimura
    • 2
  • M. Tateishi
    • 2
  • S. Higuchi
    • 1
  1. 1.Drug Metabolism LaboratoriesYamanouchi Pharmaceutical Co. LtdTokyoJapan
  2. 2.Tsukuba Laboratory, Life Science LaboratoryNemoto & Co., LtdIbarakiJapan

Personalised recommendations